S&P 500   3,971.27
DOW   32,394.25
QQQ   307.12
Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
Modern Day Options Trading For Beginners! (Ad)pixel
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
Roku And The 20% Rally That’s About To Start 
Modern Day Options Trading For Beginners! (Ad)pixel
Don't Be Fooled by These 3 Value Traps
The Bottom Is In For McCormick & Company
Modern Day Options Trading For Beginners! (Ad)pixel
Buffett's company owns nearly 24% of Occidental Petroleum
3 Undervalued Dividend Payers For Volatile Market Conditions
S&P 500   3,971.27
DOW   32,394.25
QQQ   307.12
Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
Modern Day Options Trading For Beginners! (Ad)pixel
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
Roku And The 20% Rally That’s About To Start 
Modern Day Options Trading For Beginners! (Ad)pixel
Don't Be Fooled by These 3 Value Traps
The Bottom Is In For McCormick & Company
Modern Day Options Trading For Beginners! (Ad)pixel
Buffett's company owns nearly 24% of Occidental Petroleum
3 Undervalued Dividend Payers For Volatile Market Conditions
S&P 500   3,971.27
DOW   32,394.25
QQQ   307.12
Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
Modern Day Options Trading For Beginners! (Ad)pixel
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
Roku And The 20% Rally That’s About To Start 
Modern Day Options Trading For Beginners! (Ad)pixel
Don't Be Fooled by These 3 Value Traps
The Bottom Is In For McCormick & Company
Modern Day Options Trading For Beginners! (Ad)pixel
Buffett's company owns nearly 24% of Occidental Petroleum
3 Undervalued Dividend Payers For Volatile Market Conditions
S&P 500   3,971.27
DOW   32,394.25
QQQ   307.12
Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
Modern Day Options Trading For Beginners! (Ad)pixel
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
Roku And The 20% Rally That’s About To Start 
Modern Day Options Trading For Beginners! (Ad)pixel
Don't Be Fooled by These 3 Value Traps
The Bottom Is In For McCormick & Company
Modern Day Options Trading For Beginners! (Ad)pixel
Buffett's company owns nearly 24% of Occidental Petroleum
3 Undervalued Dividend Payers For Volatile Market Conditions
NASDAQ:XLO

Xilio Therapeutics - XLO Price Target & Analyst Ratings

$3.11
+0.08 (+2.64%)
(As of 03/28/2023 12:00 AM ET)
Add
Compare
Today's Range
$3.06
$3.21
50-Day Range
$2.67
$4.28
52-Week Range
$1.95
$8.10
Volume
6,361 shs
Average Volume
29,447 shs
Market Capitalization
$85.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.25

Xilio Therapeutics Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Buy
Based on 3 Analyst Ratings

Consensus Analyst Price Target

$11.25
261.74% Upside
High Prediction$15.00
Average Prediction$11.25
Low Prediction$7.00
TypeCurrent
3/29/22 to 3/29/23
1 Month Ago
2/27/22 to 2/27/23
3 Months Ago
12/29/21 to 12/29/22
1 Year Ago
3/29/21 to 3/29/22
Consensus Rating
Buy
Buy
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
3 Buy rating(s)
3 Buy rating(s)
4 Buy rating(s)
5 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$11.25$11.25$13.75$31.50
Predicted Upside261.74% Upside314.91% Upside509.95% Upside41.89% Upside
Get Xilio Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for XLO and its competitors with MarketBeat's FREE daily newsletter.

XLO Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

XLO Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Xilio Therapeutics Stock vs. The Competition

TypeXilio TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.64
2.47
Consensus RatingBuyBuyHold
Predicted Upside261.74% Upside1,958.48% Upside202.55% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
1/27/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight$20.00 ➝ $10.00+148.14%
12/21/2022Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Barcus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$7.00+255.33%
11/15/2022Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$15.00+525.00%
11/10/2022Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$31.00 ➝ $13.00+467.68%
1/10/2022HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. King
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy
11/16/2021Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform
(Data available from 3/29/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












XLO Price Target - Frequently Asked Questions

What is Xilio Therapeutics's consensus rating and price target?

According to the issued ratings of 3 analysts in the last year, the consensus rating for Xilio Therapeutics stock is Buy based on the current 3 buy ratings for XLO. The average twelve-month price prediction for Xilio Therapeutics is $11.25 with a high price target of $15.00 and a low price target of $7.00. Learn more on XLO's analyst rating history.

Do Wall Street analysts like Xilio Therapeutics more than its competitors?

Analysts like Xilio Therapeutics more than other Medical companies. The consensus rating score for Xilio Therapeutics is 3.00 while the average consensus rating score for medical companies is 2.64. Learn more on how XLO compares to other companies.

Does Xilio Therapeutics's stock price have much upside?

According to analysts, Xilio Therapeutics's stock has a predicted upside of 314.91% based on their 12-month price targets.

What analysts cover Xilio Therapeutics?

Xilio Therapeutics has been rated by Morgan Stanley in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:XLO) was last updated on 3/29/2023 by MarketBeat.com Staff